Daily Cardiology Research Analysis
Analyzed 172 papers and selected 3 impactful papers.
Summary
The most impactful studies highlighted a mechanistic link between cold exposure and venous thrombosis, identified BCAT1-dependent proline biosynthesis as a therapeutic pathway for cardiac fibrosis, and provided randomized evidence that losartan plus prednisolone did not improve the primary cardiac endpoint in post-COVID inflammatory cardiac involvement. Together, these papers advance cardiovascular science through mechanistic discovery, translational target identification, and informative negative clinical results.
Research Themes
- Mechanisms of thrombosis and cardiovascular risk
- Targeting cardiac fibrosis and remodeling
- Randomized evaluation of post-COVID cardiac inflammation therapy
Selected Articles
1. Cold exposure aggravates vein occlusion through non-shivering thermogenesis-induced thrombocytopoiesis.
Using mouse models, human volunteers, and retrospective clinical cohorts, this study demonstrated that cold exposure aggravates venous occlusion by increasing platelet production. Adipose thermogenesis elevated circulating free fatty acids, which enhanced acetyl-CoA production and activated the C/EBPα-GATA-1/NF-E2 megakaryocyte maturation pathway. Inhibition of adipose lipolysis, CPT1α, or p300 reduced thrombocytopoiesis and venous thrombosis in experimental models.
Impact: The study connects an epidemiologically observed seasonal increase in venous thrombosis to a defined adipose–metabolic–megakaryocyte mechanism. It also identifies druggable metabolic nodes that could support new preventive strategies for venous thromboembolism.
Clinical Implications: The findings support consideration of seasonal and environmental cold exposure as potential modifiers of venous thrombotic risk, particularly in susceptible individuals. CPT1α, p300, adipose lipolysis, and megakaryocyte metabolic pathways are investigational targets and should not yet be used clinically for thrombosis prevention.
Key Findings
- Cold exposure increased platelet counts and aggravated deep venous thrombosis and retinal vein occlusion in mouse models.
- Adipose thermogenesis increased free fatty acids, promoting acetyl-CoA production and C/EBPα stabilization through p300-SIRT1 balance.
- Inhibition of PNPLA2, CPT1α, or p300 reduced cold-induced thrombocytopoiesis and venous occlusion.
- Healthy volunteers and retrospective patient cohorts showed increased platelet counts or venous thrombosis during cold exposure or cold seasons.
Methodological Strengths
- Integrated mechanistic experiments in multiple mouse models with pharmacological and genetic interventions.
- Translational triangulation using healthy volunteers and retrospective human clinical cohorts.
Limitations
- The causal intervention experiments were performed primarily in mice, and human observational data cannot establish clinical causality.
- The human retrospective cohorts were relatively small and may be affected by seasonal, demographic, and behavioral confounding.
Future Directions: Prospective human studies should test whether cold exposure independently increases venous thromboembolism risk and should evaluate platelet and metabolic biomarkers. Translation of CPT1α or p300 inhibition into clinical prevention will require rigorous safety, dosing, and target-specificity studies.
Vein occlusion (VO), including deep venous thrombosis (DVT) and retinal vein occlusion (RVO), is a common cause of multiple diseases that severely compromise the quality of life of affected individuals. Epidemiological evidence indicates that VO prevalence increases in cold seasons, yet the underlying mechanism remains unknown. Here, we show that cold exposure markedly elevates peripheral platelet counts, thereby aggravating VO in mouse models. Cold-augmented thrombocytopoiesis depends on the activation of adipose thermogenesis and subsequent increase in circulating free fatty acid (FFA) levels.
2. Branched chain amino acid transaminase 1-mediated pathway promotes proline-dependent collagen production in cardiac myofibroblasts.
This study identified BCAT1 as a metabolic regulator of collagen production in cardiac myofibroblasts. BCAT1-derived branched-chain amino acids promoted HDAC5 phosphorylation and SMAD3 activation, inducing transcription of proline-biosynthesis genes. BCAT1 deficiency or pharmacological inhibition reduced collagen production and cardiac fibrosis after myocardial infarction in mice.
Impact: The paper links amino-acid metabolism directly to extracellular matrix production and cardiac fibrosis, moving beyond descriptive fibroblast biology. BCAT1 provides a mechanistically defined and potentially druggable target for limiting pathological remodeling after myocardial infarction.
Clinical Implications: BCAT1 inhibition could eventually represent an antifibrotic strategy after myocardial infarction or in other fibrotic cardiovascular diseases. However, clinical use is premature because efficacy, cardiac specificity, metabolic toxicity, and effects on normal wound healing remain untested in humans.
Key Findings
- BCAT1 was upregulated in proto-myofibroblast-like fibroblasts and myofibroblasts in fibrotic mouse and human tissues.
- BCAT1-mediated branched-chain amino-acid production promoted HDAC5 phosphorylation, SMAD3 activation, and transcription of Aldh18a1, Pycr1, and Eprs.
- BCAT1-deficient mice showed reduced proline-biosynthesis gene expression and less cardiac fibrosis after myocardial infarction.
- Pharmacological BCAT1 inhibition reduced cardiac fibrosis in mice, supporting BCAT1 as a therapeutic target.
Methodological Strengths
- Mechanistic validation across human and mouse fibrotic tissues, genetic loss-of-function models, and pharmacological inhibition.
- Integration of cellular, biochemical, transcriptional, and in vivo cardiac fibrosis readouts.
Limitations
- The therapeutic experiments were conducted in mice, and the clinical efficacy and safety of BCAT1 inhibition in humans are unknown.
- The abstract does not establish whether BCAT1 inhibition preserves beneficial repair processes or causes systemic metabolic effects.
Future Directions: Future work should define the therapeutic window and cardiac selectivity of BCAT1 inhibition, evaluate effects on ventricular function and arrhythmia, and test the pathway in large-animal models. Human tissue studies should determine whether BCAT1 expression predicts fibrotic progression or response to antifibrotic therapy.
Myofibroblasts are the cells responsible for collagen production, leading to tissue fibrosis. Because 20.5% of the total amino acids in collagen are proline, myofibroblasts must acquire a well-developed proline-producing mechanism during their differentiation. However, the detailed mechanism for myofibroblasts to acquire and keep the developed proline biosynthesis machinery remains obscure. Here, we show branched-chain amino acid transaminase 1 (Bcat1) is up-regulated in a substantial subset of Postn-expressing proto-myofibroblast-like fibroblasts, transitional cells en route to fully differentiated myofibroblasts, as well as in myofibroblasts in the fibrotic heart and liver of mice and humans and promotes the proline production.
3. Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial.
In the multicenter Myoflame-19 randomized, double-blind trial, 279 participants with post-COVID syndrome and cardiovascular magnetic resonance-defined inflammatory cardiac involvement received losartan plus prednisolone or placebo for 16 weeks. The primary endpoint, change in left ventricular ejection fraction, was not significantly different between groups. Several symptom and imaging outcomes numerically favored treatment, but confidence intervals included no effect and were considered hypothesis-generating.
Impact: This is a rigorous randomized test of an empirically plausible anti-inflammatory strategy for a clinically important but treatment-deficient post-COVID cardiac syndrome. The neutral primary result is valuable because it discourages premature adoption of immunomodulation and refines the design of future phenotype-specific trials.
Clinical Implications: Losartan plus prednisolone should not be routinely prescribed to improve cardiac function in post-COVID syndrome with inflammatory cardiac involvement based on this trial. Clinical management should remain individualized, with continued evaluation for alternative causes of symptoms and enrollment in well-designed clinical studies when appropriate.
Key Findings
- The trial randomized 279 participants to losartan plus prednisolone or matching placebo for 16 weeks.
- The primary endpoint of change in left ventricular ejection fraction was neutral, with a between-group difference of 0.74 percentage points and p=0.10.
- Several symptom and cardiac magnetic resonance measures numerically favored treatment, but their confidence intervals included the null value.
- Treatment was reported to be safe and well tolerated.
Methodological Strengths
- Multicenter randomized, double-blind, placebo-controlled design with cardiovascular magnetic resonance-based eligibility criteria.
- Prospective registration and modified intention-to-treat analysis with prespecified primary and secondary outcomes.
Limitations
- The modified intention-to-treat population was smaller than the randomized population, with 124 and 122 participants analyzed in the two groups.
- The 16-week treatment and follow-up period may be insufficient to detect effects on longer-term remodeling, symptoms, or clinical events.
- Several secondary findings were imprecise and exploratory because their confidence intervals included the null.
Future Directions: Future trials should use biologically enriched phenotypes, longer follow-up, and clinical endpoints such as symptom recovery, hospitalization, arrhythmia, and persistent myocardial injury. Biomarker-guided analyses may identify subgroups that could benefit from anti-inflammatory or renin-angiotensin system-directed therapy.
Persistent cardiac symptoms are common in post-COVID syndrome, even without structural heart disease. Evidence implicates immune dysregulation, endothelial dysfunction and low-grade cardiovascular inflammation. Yet no targeted treatment exists. Myoflame-19 is a multicenter, double-blind clinical trial of 279 participants with inflammatory cardiac involvement defined by cardiovascular magnetic resonance, randomized 1:1 to losartan plus prednisolone (n = 139) or matching placebos (n = 140) for 16 weeks. The modified intention-to-treat population comprised 124 and 122 participants. The primary endpoint, change in left ventricular (LV) ejection fraction, was neutral: between-group difference 0.74 percentage points (pp), 95%CI -0.14 to 1.62, p = 0.10.